Abstract
We herein report the synthesis of 3β-substituted amides of 17a-aza-D-homo-4-androsten-17-one (11a-11r) from commercially available Diosgenin as the starting material. The structures of newly synthesized compounds were confirmed by IR, 1H NMR, 13C NMR and mass spectrometry. All the synthesized analogues were tested for their 5α- reductase inhibitory and antimicrobial activity, some of them exhibit moderate to potent activity comparable to the reference drugs. Among the synthesized derivatives the analogue (11r) 3β-(indonlylbutanamido)-17a-aza-D-homo-4- androsten-17-one was found to be active against both 5-reductase enzyme and microbial strains, whereas the analogue (11i) 3β-(3,4-dimethoxy-benzamido)-17a-aza-D-homo-4-androsten-17-one was found to be the least active. The detailed 5-reductase inhibitors and antimicrobial activities of the synthesized compounds were reported.
Keywords: 5α-Reductase, Antibacterial, Antifungal, Dutasteride, Ciprofloxacin, Voriconazole.
Current Topics in Medicinal Chemistry
Title:Synthesis and Characterization of 3β-Substituted Amides of 17a-Aza-Dhomo- 4-androsten-17-one as Potent 5α-Reductase Inhibitors and Antimicrobial Agents
Volume: 13 Issue: 16
Author(s): Manav Malhotra, Rajiv Sharma, Ravindra K. Rawal, Hemraj Heer and T. R. Bhardwaj
Affiliation:
Keywords: 5α-Reductase, Antibacterial, Antifungal, Dutasteride, Ciprofloxacin, Voriconazole.
Abstract: We herein report the synthesis of 3β-substituted amides of 17a-aza-D-homo-4-androsten-17-one (11a-11r) from commercially available Diosgenin as the starting material. The structures of newly synthesized compounds were confirmed by IR, 1H NMR, 13C NMR and mass spectrometry. All the synthesized analogues were tested for their 5α- reductase inhibitory and antimicrobial activity, some of them exhibit moderate to potent activity comparable to the reference drugs. Among the synthesized derivatives the analogue (11r) 3β-(indonlylbutanamido)-17a-aza-D-homo-4- androsten-17-one was found to be active against both 5-reductase enzyme and microbial strains, whereas the analogue (11i) 3β-(3,4-dimethoxy-benzamido)-17a-aza-D-homo-4-androsten-17-one was found to be the least active. The detailed 5-reductase inhibitors and antimicrobial activities of the synthesized compounds were reported.
Export Options
About this article
Cite this article as:
Malhotra Manav, Sharma Rajiv, Rawal K. Ravindra, Heer Hemraj and Bhardwaj R. T., Synthesis and Characterization of 3β-Substituted Amides of 17a-Aza-Dhomo- 4-androsten-17-one as Potent 5α-Reductase Inhibitors and Antimicrobial Agents, Current Topics in Medicinal Chemistry 2013; 13 (16) . https://dx.doi.org/10.2174/15680266113139990131
DOI https://dx.doi.org/10.2174/15680266113139990131 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Epigenetics, Depression and Antidepressant Treatment
Current Pharmaceutical Design Age-related Changes in Respiratory Function and Daily Living. A Tentative Model Including Psychosocial Variables, Respiratory Diseases and Cognition
Current Aging Science Role of Epithelial Mesenchymal Transition in Prostate Tumorigenesis
Current Pharmaceutical Design A Preliminary Assessment of the Structure-Activity Relationship of Benzimidazole-Based Anti-Proliferative Agents
Letters in Drug Design & Discovery Synthesis and Evaluation of Cytotoxicity of Novel Coumarin Peptide Alcohol Derivatives
Medicinal Chemistry Effect of Environmental Substances on the Activity of Arylamine N-Acetyltransferases
Current Drug Metabolism Persistent GP130/STAT3 Signaling Contributes to the Resistance of Doxorubicin, Cisplatin, and MEK Inhibitor in Human Rhabdomyosarcoma Cells
Current Cancer Drug Targets Receptor-Based Design of Cytokine Therapeutics
Current Pharmaceutical Biotechnology Pre-Clinical Considerations in the Assessment of Immunogenicity for Protein Therapeutics
Current Drug Safety Effect of Flavonoids on Human Health: Old Subjects but New Challenges
Recent Patents on Biotechnology The Complex Biology of FOXO
Current Drug Targets Patent Selections:
Recent Patents on Anti-Cancer Drug Discovery Efficient siRNA Delivery Using PEG-conjugated PAMAM Dendrimers Targeting Vascular Endothelial Growth Factor in a CoCl2-induced Neovascularization Model in Retinal Endothelial Cells
Current Drug Delivery Radio-thermo-sensitivity Induced by Gold Magnetic Nanoparticles in the Monolayer Culture of Human Prostate Carcinoma Cell Line DU145
Anti-Cancer Agents in Medicinal Chemistry Selenium and Cardiovascular Surgery: An Overview
Current Drug Safety Matrix Metalloproteinase Inhibitors as Prospective Agents for the Prevention and Treatment of Cardiovascular and Neoplastic Diseases
Current Topics in Medicinal Chemistry A Single Center Phase II Study of Continuous Infusion of Low-dose 5- fluorouracil for Heavily Pretreated Patients With Metastatic Colorectal Cancer
Clinical Cancer Drugs Phytoestrogen Genistein and Its Pharmacological Interactions with Synthetic Endocrine-Active Compounds
Current Pharmaceutical Design Salinomycin: A Novel Anti-Cancer Agent with Known Anti-Coccidial Activities
Current Medicinal Chemistry Dimerization and Ion Binding Properties of S100P Protein
Protein & Peptide Letters